DiaMedica Therapeutics Inc. Stockholders Equity

Quick Answer

DiaMedica Therapeutics Inc. reported Stockholders Equity of $56.11 million for fiscal year 2025.

DiaMedica Therapeutics Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $56.11M +37.8%
2024 $40.72M -20.2%
2023 $51.06M +60.4%
2022 $31.83M -27.7%
2021 $44.02M +69.2%
2020 $26.01M +241.5%
2019 $7.62M -55.3%
2018 $17.02M +2030.8%
2017 $799.0K -28.1%
2016 $1.11M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $51.62M +7.6% +90.0%
June 30, 2025 $27.17M -49.1% -20.0%
March 31, 2025 $33.95M -26.7% -16.6%
December 31, 2024 $40.72M -20.2% -15.1%
September 30, 2024 $47.96M -13.8% -10.2%
June 30, 2024 $53.41M -10.6% +15.2%
March 31, 2024 $46.35M +71.5% -9.2%
December 31, 2023 $51.06M +60.4% -8.2%
  • DiaMedica Therapeutics Inc. showed an increase of +37.8% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2016–2025 period, DiaMedica Therapeutics Inc.’s stockholders equity has grown by 4950.5% (from $1.11 million to $56.11 million).
  • The most recent figure is from DiaMedica Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment